2007-2008 Influenza Season
Week 8, ending February 23, 2008
(All data are preliminary and may change as more reports are received.)

Synopsis: During week 8 (February 17 - 23, 2008), influenza activity decreased slightly in the United States.

- Two thousand three hundred twenty-one (30.0%) specimens tested by U.S. World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories were positive for influenza.
- The proportion of deaths attributed to pneumonia and influenza was above the epidemic threshold for the seventh consecutive week.
- The proportion of outpatient visits for influenza-like illness (ILI) and acute respiratory illness (ARI) was above national baseline levels. ILI decreased in seven of the nine regions compared to week 7, and was above region-specific baselines in all nine regions. The East South Central, Mid-Atlantic, Mountain, New England, Pacific, South Atlantic and West North Central regions reported ARI at or above their region specific baselines.
- Forty-nine states reported widespread influenza activity; one state reported regional influenza activity; and the District of Columbia reported local influenza activity.

National and Regional Summary of Select Surveillance Components

<table>
<thead>
<tr>
<th>Region</th>
<th>Data for current week</th>
<th>Data cumulative for the season</th>
<th>Sentinel Provider ILI*</th>
<th>DoD and VA ARI*</th>
<th>% pos. for flu†</th>
<th>Number of jurisdictions reporting regional or widespread activity‡</th>
<th>A (H1)</th>
<th>A (H3)</th>
<th>A Unsub-typed</th>
<th>B</th>
<th>Pediatric Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nation</td>
<td>Elevated</td>
<td>Elevated</td>
<td>30.0%</td>
<td>50 of 51</td>
<td>1416</td>
<td>2794</td>
<td>11252</td>
<td>3461</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>Elevated</td>
<td>Elevated</td>
<td>26.4%</td>
<td>6 of 6</td>
<td>50</td>
<td>32</td>
<td>423</td>
<td>357</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mid-Atlantic</td>
<td>Elevated</td>
<td>Elevated</td>
<td>27.7%</td>
<td>3 of 3</td>
<td>66</td>
<td>40</td>
<td>553</td>
<td>626</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>East North Central</td>
<td>Elevated</td>
<td>Normal</td>
<td>40.8%</td>
<td>5 of 5</td>
<td>124</td>
<td>586</td>
<td>448</td>
<td>249</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>West North Central</td>
<td>Elevated</td>
<td>Elevated</td>
<td>30.1%</td>
<td>7 of 7</td>
<td>65</td>
<td>94</td>
<td>1064</td>
<td>277</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>South Atlantic</td>
<td>Elevated</td>
<td>Elevated</td>
<td>33.9%</td>
<td>8 of 9</td>
<td>236</td>
<td>1043</td>
<td>3027</td>
<td>662</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>East South Central</td>
<td>Elevated</td>
<td>Elevated</td>
<td>42.4%</td>
<td>4 of 4</td>
<td>26</td>
<td>397</td>
<td>58</td>
<td>14</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>West South Central</td>
<td>Elevated</td>
<td>Normal</td>
<td>33.3%</td>
<td>4 of 4</td>
<td>86</td>
<td>324</td>
<td>4539</td>
<td>596</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mountain</td>
<td>Elevated</td>
<td>Elevated</td>
<td>28.3%</td>
<td>8 of 8</td>
<td>364</td>
<td>203</td>
<td>628</td>
<td>417</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pacific</td>
<td>Elevated</td>
<td>Elevated</td>
<td>15.8%</td>
<td>5 of 5</td>
<td>399</td>
<td>75</td>
<td>512</td>
<td>266</td>
<td>4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Elevated means the % of visits for ILI or ARI is at or above the national or region-specific baseline
† National data are for current week; regional data are for the most recent three weeks
‡ Includes all 50 states and the District of Columbia
**Laboratory Surveillance:** During week 8, WHO and NREVSS laboratories reported 7,726 specimens tested for influenza viruses, 2,321 (30.0%) of which were positive, including 67 influenza A (H1) viruses, 437 influenza A (H3) viruses, 1,193 influenza A viruses that were not subtyped, and 624 influenza B viruses.

Since September 30, 2007, WHO and NREVSS laboratories have tested a total of 122,962 specimens for influenza viruses and 18,923 (15.4%) were positive. Among the 18,923 influenza viruses, 15,462 (81.7%) were influenza A viruses and 3,461 (18.3%) were influenza B viruses. Four thousand two hundred ten (27.2%) of the 18,923 influenza A viruses have been subtyped: 1,416 (33.6%) were influenza A (H1) viruses and 2,794 (66.4%) were influenza A (H3) viruses.

Although influenza A (H1) viruses predominated through mid-January, an increasing proportion of subtyped influenza A viruses are influenza A (H3) viruses. Influenza A (H3) viruses have been reported more frequently than influenza A (H1) viruses since week 4 (January 20-26), and during week 6, influenza A (H3) became the predominant virus for the season overall. This season influenza A (H3) viruses have been reported more frequently than A (H1) viruses nationally, as well as in five of the nine surveillance regions (East North Central, East South Central, South Atlantic, West North Central, and West South Central). Influenza A (H1) viruses have predominated circulation this season in the remaining four regions (Mid-Atlantic, Mountain, New England, and Pacific).

**Composition of the 2008-09 Influenza Vaccine:** WHO and FDA have recommended that the 2008-09 trivalent influenza vaccine for the Northern Hemisphere contain A/Brisbane/59/2007-like (H1N1), A/Brisbane/10/2007-like (H3N2), and B/Florida/4/2006-like viruses. All three components have been changed from the 2007-08 Northern Hemisphere vaccine formulation. A/Brisbane/10/2007-like (H3N2) and B/Florida/4/2006-like viruses are currently included in the 2008 Southern Hemisphere vaccines. This recommendation was based on surveillance data related to epidemiology and antigenic characteristics, serological responses to 2007-08 vaccines, and the availability of candidate strains and reagents.
**Antigenic Characterization:** CDC has antigenically characterized 303 influenza viruses [157 influenza A (H1N1), 77 influenza A (H3N2), and 69 influenza B viruses] collected by U.S. laboratories since September 30, 2007.

**Influenza A (H1N1) [157]**
- One hundred twenty-four (79%) of the 157 viruses were characterized as A/Solomon Islands/3/2006-like, the influenza A (H1N1) component of the 2007-08 influenza vaccine for the Northern Hemisphere and the 2008 influenza A (H1N1) component for the Southern Hemisphere.
- Nineteen (12%) of the 157 viruses showed somewhat reduced titers with antisera produced against A/Solomon Islands/3/2006.
- Fourteen (9%) of the 157 viruses were characterized as A/Brisbane/59/2007-like. A/Brisbane/59/2007 is a recent genetic/antigenic variant which evolved from A/Solomon Islands/03/2006. An A/Brisbane/59/2007-like virus is the WHO recommended strain for the 2008-09 Northern Hemisphere vaccine formulation.

**Influenza A (H3N2) [77]**
- Twelve (16%) of the 77 viruses were characterized as A/Wisconsin/67/2005-like, the influenza A (H3N2) component of the 2007-08 influenza vaccine for the Northern Hemisphere.
- Sixty-one (79%) of the 77 viruses were characterized as A/Brisbane/10/2007-like. A/Brisbane/10/2007-like viruses are a recent antigenic variant which evolved from, but are antigenically distinct from, A/Wisconsin/67/2005-like viruses. A/Brisbane/10/2007-like virus is the recommended influenza A (H3N2) component for the 2008 Southern Hemisphere and 2008-09 Northern Hemisphere vaccines.
- Four (5%) of the 77 viruses showed somewhat reduced titers with antisera produced against A/Wisconsin/67/2005 and A/Brisbane/10/2007.

**Influenza B (B/Victoria/02/87 and B/Yamagata/16/88 lineages) [69]**

**Victoria lineage [4]**
- Four (6%) of the 69 influenza B viruses characterized belong to the B/Victoria lineage of viruses.
  - Two (50%) of these 4 viruses were characterized as B/Ohio/01/2005-like. The recommended influenza B component for the 2007-08 influenza vaccine is a B/Malaysia/2506/2004-like virus, belonging to the B/Victoria lineage. B/Ohio/01/2005 is a recent B/Malaysia/2506/2004-like reference strain.
  - Two (50%) of these 4 viruses showed somewhat reduced titers with antisera produced against B/Ohio/01/2005 and B/Malaysia/2506/2004.

**Yamagata lineage [65]**
- Sixty-five (94%) of the 69 viruses were identified as belonging to the B/Yamagata lineage of viruses. The recommended influenza B component for the 2008-09 Northern Hemisphere vaccine is a B/Florida/4/2006-like virus which belongs to the B/Yamagata lineage.

These data indicate similarities and differences between a sample of circulating strains and this year's vaccine strains as determined by laboratory studies. Clinical vaccine effectiveness cannot be accurately predicted using these data, and in previous years, influenza vaccination has been shown to provide measurable protection against influenza illness and influenza-related complications, even when vaccine strains are antigenically distinct from circulating strains.
**Antiviral Resistance:** In the United States, two groups of antiviral drugs have been approved by FDA for use in treating or preventing influenza infections. These two groups of antiviral drugs are: neuraminidase inhibitors (oseltamivir and zanamivir) and adamantanes (amantadine and rimantidine). A description of these drugs can be found at: [http://www.cdc.gov/flu/protect/antiviral/index.htm](http://www.cdc.gov/flu/protect/antiviral/index.htm).

**Neuraminidase Inhibitor Antiviral Drugs:** Of the 557 influenza A and B viruses from the United States tested for antiviral resistance so far this season, 38 (6.8%) have been found to be resistant to oseltamivir. Currently all of the resistant viruses are H1N1 viruses, with 38 (9.6%) of 395 H1N1 viruses tested exhibiting a genetic mutation that confers oseltamivir resistance. These resistant viruses have been found sporadically across five of the nine surveillance regions. All tested viruses retain their sensitivity to zanamivir. Additional information on antiviral resistance can be found at: [http://www.cdc.gov/flu/about/qa/antiviralresistance.htm](http://www.cdc.gov/flu/about/qa/antiviralresistance.htm).

**Adamantane Antiviral Drugs:** Resistance to the adamantanes continues to be high. Among 429 influenza A viruses tested, 103 (24.0%) are resistant to adamantanes, including 98.9% of H3N2 viruses and 4.7% of H1N1 viruses. The adamantanes are not effective against influenza B viruses.

Based on the level of oseltamivir resistance observed in only one influenza subtype, H1N1, and persisting high levels of resistance to the adamantanes in both H3N2 and H1N1 viruses, CDC continues to recommend the use of oseltamivir and zanamivir for the treatment or prevention of influenza. Use of amantadine or rimantadine is not recommended. Guidance on influenza antiviral use can be found at: [http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5606a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5606a1.htm).
**Pneumonia and Influenza (P&I) Mortality Surveillance:** During week 8, 8.2% of all deaths reported through the 122 Cities Mortality Reporting System were reported as due to P&I. This percentage is above the epidemic threshold of 7.2% for week 8. Including week 8, P&I mortality has been above threshold for seven consecutive weeks.

**Pneumonia and Influenza Mortality for 122 U.S. Cities**

Week Ending 02/23/2008

**Influenza-Associated Pediatric Mortality:** Three influenza-associated pediatric deaths were reported to CDC during week 8 (CA, NV, and VA). One death previously reported was reclassified as not a case. Since September 30, 2007, CDC has received a total of 24 reports of influenza-associated pediatric deaths that occurred during the current season.

**Number of Influenza-Associated Pediatric Deaths by Week of Death:**

2005-06 season to present
Influenza-Associated Pediatric Hospitalizations: Laboratory-confirmed influenza-associated pediatric hospitalizations are monitored in two population-based surveillance networks: the New Vaccine Surveillance Network (NVSN) and the Emerging Infections Program (EIP). These two systems provide updates of surveillance data every two weeks. As a result of differing dates for initiating surveillance in the 2007-08 season, these updates occur on alternating weeks.

During November 4, 2007-February 9, 2008, the preliminary laboratory-confirmed influenza-associated hospitalization rate reported by the NVSN for children 0-4 years old was 1.83 per 10,000.

![NVSN Influenza Laboratory-Confirmed Cumulative Hospitalization Rates for Children 0 - 4 Years, 2007-08 and Previous 2 Seasons](image-url)
During September 30 – February 16, 2008, the preliminary laboratory-confirmed influenza-associated hospitalization rate reported by the EIP for children 0–17 years old was 0.57 per 10,000. For children aged 0-4 years and 5-17 years, the rate was 1.54 per 10,000 and 0.18 per 10,000, respectively.

**EIP Influenza Laboratory-Confirmed Cumulative Hospitalization Rates for Children Aged 0-4 and 5-17 yrs, 2007-2008 and Previous 2 Seasons**

**Outpatient Illness Surveillance:** Nationwide during week 8, 5.7% of outpatient visits reported through the U.S. Influenza Sentinel Provider Surveillance Network were due to influenza-like illness (ILI), which is above the national baseline of 2.2%. On a regional level, the percentage of visits for ILI decreased in seven of the nine regions compared to last week and ranged from 3.6% to 8.8%. All nine regions reported ILI above their region-specific baselines.

Starting in week 5, New York City began reporting ILI data collected electronically from emergency departments city-wide, adding approximately 60,000 additional patient visits per week to the U.S. Influenza Sentinel Provider Surveillance Network. Retrospective reports were submitted for all earlier weeks this season. While this change increases the total patient visits per week by approximately 15%, it is not expected to influence the national ILI outpatient visit percentage after population weighting, but may have a larger impact on the Mid-Atlantic regional ILI percentage.

During week 8, 3.5% of patient visits to Department of Veteran’s Affairs (VA) and Department of Defense (DoD) outpatient treatment facilities were for acute respiratory illness (ARI), which was above the national baseline of 3.2%. On a regional level, the percentage of visits for ARI ranged from 1.8% to 4.2%, and was at or above the region-specific baselines in seven of the nine regions (East South Central, Mid-Atlantic, Mountain, New England, Pacific, South Atlantic and West North Central). The percentage of visits reported for ARI was at or above age-specific baselines in the 5-17 years, 18-49 years, 50-64 years, and >64 years age groups.
**Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:** During week 8 the following influenza activity was reported:

- Widespread activity was reported by 49 states (Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, Wisconsin, West Virginia, and Wyoming).
- Regional activity was reported by 1 state (Florida).
- The District of Columbia reported local influenza activity.

---

A description of surveillance methods is available at: [http://www.cdc.gov/flu/weekly/fluactivity.htm](http://www.cdc.gov/flu/weekly/fluactivity.htm)